SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Wednesday reported a loss of $42.2 million in its fourth quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 28 cents.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.
The biopharmaceutical company posted revenue of $37.5 million in the period, which also did not meet Street forecasts. Five analysts surveyed by Zacks expected $42.5 million.
For the year, the company reported that its loss widened to $153.5 million, or $1.10 per share. Revenue was reported as $165.4 million.
Nektar shares have increased 6 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $13.01, a climb of 13 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR
Keywords: Nektar Therapeutics, Earnings Report